Shield Therapeutics PLC (STX)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

5.70p

Buy

5.90p

arrow-down-0.49p (-7.72%)

Prices updated at 26 May 2026, 16:35 BST

Prices minimum 15 mins delay

Prices in GBX

Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.

FTSE All-Share

0.29%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Mr. Hans Peter Hasler

CEO

Mr. Karl Anders Lundstrom

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

68

Head office

Gateshead Quays

Newcastle

United Kingdom

NE8 3DF

+44 1915118500

investorrelations@shieldtx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Peter Hermann William Llewellyn-Davies Non-Executive Director, Vice Chairman	-
Mr. Hans Peter Hasler Non-Executive Director, Chairman	-
Ms. Maria Fabiana Lacerca-Allen Non-Executive Director	-
Dr. Christian Schweiger Non-Executive Director	-
Mr. Karl Anders Lundstrom Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Mandarine Gestion	6,150,000
Miton Asset Management Limited	5,725,916
Premier Miton UK Smaller Companies	5,725,916
Mandarine Europe Microcap	5,500,000
IFSL Marlborough Nano Cap Growth Fund	1,250,000

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.